Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
The Breast Journal|November 18, 2003
Clinical experience with trastuzumab (herceptin)Charles L Vogel, Sandra X FrancoThe Oncologist|February 17, 2010
Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancerLee S Schwartzberg, Lee S Schwarzberg, Sandra X Franco, et al.Cancer Chemotherapy and Pharmacology|March 19, 2009
A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancerOlivier Rixe, Sandra X Franco, Denise A Yardley, et al.The Oncologist|May 24, 2013
An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancerFrancisco J Esteva, Sandra X Franco, Maura K Hagan, et al.Breast Cancer Research and Treatment|December 27, 2011
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancerHope S Rugo, A Jo Chien, Sandra X Franco, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2008
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancerHenry L Gomez, Dinesh C Doval, Miguel A Chavez, et al.Breast (Edinburgh, Scotland)|June 19, 2024
6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)Fatima Cardoso, Shani Paluch-Shimon, Eva Schumacher-Wulf, et al.Pageof 1